The startup develops an anti-infective drug specifically targeting the pathogens responsible for periodontitis, providing a precise treatment alternative to broad-spectrum antibiotics. This targeted approach enables healthcare providers to effectively prevent disease recurrence while minimizing the impact on beneficial oral microbiota.
Funding
$6.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Periodontitis, an inflammatory gum disease caused by pathogenic bacteria, leads to receding gums, bone and tooth loss, and can contribute to chronic diseases. Current treatments often involve painful manual plaque removal and broad-spectrum antibiotics, which can disrupt the beneficial oral microbiota and increase the risk of disease recurrence.
Solution
PerioTrap Pharmaceuticals is developing selective, small-molecule drugs that precisely target and inhibit the pathogenic bacteria responsible for periodontitis, while preserving the beneficial commensal bacteria in the oral microbiome. This targeted approach supports the growth of healthy bacteria, helping to restore the natural barrier function of the microbiome and reduce the likelihood of future infections. By modulating the microbiome, PerioTrap aims to provide a more effective and less disruptive treatment option compared to traditional methods. The company's pipeline includes programs focused on novel periodontal therapeutics, exploring alternative metal-binding groups, and controlled-release drug delivery systems.
Target Audience
The primary target audience includes dental healthcare providers seeking more effective and targeted treatments for periodontitis, as well as patients at risk of or currently suffering from the disease.
Features
- Selective targeting of disease-causing bacteria to minimize impact on commensal bacteria
- Small-molecule drug design for precise action
- Microbiome modulator to support a shift towards a natural, healthy oral environment
- Focus on preventing disease recurrence by maintaining a balanced microbiome
- Development of controlled-release drug delivery systems for sustained therapeutic effect
- Research into alternative metal-binding groups to enhance drug efficacy
- Publicly funded programs advancing novel periodontitis therapeutics